{ "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583", "docSlug": "f06b0b5d2079", "documentTitle": "Soleno Therapeutics (SLNO)", "authorId": "58_Scorpion_Capital", "authorName": "Scorpion Capital", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "short_seller", "sourceTypeLabel": "Short seller", "presentationDate": "2025-08-15 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 295, "pageCount": 415, "prevPage": 294, "nextPage": 296, "slideType": "expose_contradiction", "function": "expose_contradiction", "density": "dense", "nDataPoints": 0, "notes": "The slide uses a Q&A transcript format to highlight negative sentiment from a key opinion leader.", "elementsJson": [ "paragraph", "quote_block", "footnote" ], "metadataConfidence": 1, "imagePath": null, "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/295", "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583", "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-295", "components": [ { "bbox": null, "kind": "callout", "text": "I don’t really see any difference...and that’s an issue.", "attrs": null, "subkind": null, "toolName": "Visual emphasis", "toolSlug": "visual-emphasis", "confidence": null, "componentId": "019dd953-64ce-7561-b2af-805a16559faf", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.05, "w": 0.86, "x": 0.07, "y": 0.38 }, "kind": "paragraph", "text": "No enthusiasm for Vykat from PWS practitioners; moved on after the trials with little interest in the drug; no observable change in patients on drug during the trial; hyperphagia endpoint was subjective and unreliable", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "fb329293-9076-4bdd-9c0e-0fedf684e89d", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.45, "w": 0.86, "x": 0.07, "y": 0.43 }, "kind": "quote", "text": "Q: “Are you hearing from any other physicians out there about the drug?” A: “Yeah. They’re wondering - should we try to switch directions? Well, they’ve stopped enrolling. The concern is okay now what other drug — because it's been around for a long time now, it's got approval now. There must be enough concern potentially, that there may be something else out there that still could help us better. What other companies, what other drugs should we think about pursuing for treating Prader-Willi Syndrome?” Q: “So, are you saying they’ve basically moved on? They don’t plan to use the drug. They’re kind of looking for something better?” A: “I think so. I think there's something better out there. I think some trials, like we talked about, the Zafgen trial before, we didn't need a statistician. We could see the patient walking in a room after every six weeks examination that, wow, there's a big difference here — twenty feet away, you can see the difference. We didn't need a statistician to find the difference. We could see it walking in. I don't think anyone felt that — I can't speak for everybody — but when I saw the patients multiple times in the years we were doing the study, I said, well, they look about the same, looks about the same. I don't really see any difference. When I fill out the form, I'd say, well, don't really see anything different. And that's an issue. You've got to have something that's objective. If mom fills out the form and dad fills out the form, you've got different answers. It shouldn't be a form. It should be something that you can objectively measure. Not something that depends from day to day.” - Trial investigator and physician; one of the leading KOL's in the PWS field", "attrs": null, "subkind": "testimonial", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "eaa6ba98-334e-4125-800e-b596ea505c93", "frameworkName": null, "frameworkSlug": null }, { "bbox": null, "kind": "quote", "text": "“Yeah. They’re wondering - should we try to switch directions? Well, they’ve stopped enrolling. The concern is okay now what other drug — because it's been around for a long time now, it's got approval now. There must be enough concern potentially, that there may be something else out there that still could help us better. What other companies, what other drugs should we think about pursuing for treating Prader-Willi Syndrome?” — Trial investigator and physician; one of the leading KOL’s in the PWS field", "attrs": null, "subkind": null, "toolName": "Authority citation", "toolSlug": "authority-citation", "confidence": null, "componentId": "019dd953-64ce-7561-b2af-84325f9c5914", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.02, "w": 0.25, "x": 0.07, "y": 0.95 }, "kind": "source-note", "text": "Source: Scorpion Capital consultation calls with experts", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "e3a0ede1-19d6-40ee-8e1b-d66db0db35c3", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.25, "w": 0.86, "x": 0.07, "y": 0.07 }, "kind": "title", "text": "Trial investigator #1 stated that the other Vykat trial investigators - who collectively manage a large percentage of PWS patients nationally and to whom the rest of the field’s practitioners look to for guidance – don’t plan to use the drug and have simply moved on to other trials and drug candidates now that that Soleno trials are over: “well, they’ve stopped enrolling...what other drugs should we think about pursuing...when I saw the patients multiple times in the years we were doing the study, I said, well, they look about the same...I don’t really see any difference...and that’s an issue.”", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "dbdbe015-9dfb-4fbd-964e-f46186cf24df", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }